European Urology Open Science最新文献

{"title":"20 Ablation of recurrent bladder tumors by cold plasma - First in human study","authors":"Dotan Z., Luder A.L., Mahmud H.M., Kleinmann N.K., Perezb D.F., Dothanb D.D., Rosenzweig B.R., Chertin B.C., Laufer M.L.","doi":"10.1016/S2666-1683(25)00024-2","DOIUrl":"10.1016/S2666-1683(25)00024-2","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S23"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Additional Active Treatment for Prostate Cancer on Health-related Quality of Life of Men: Results from the EUPROMS 2.0 1-year Follow-up Survey","authors":"Lionne D.F. Venderbos ,&nbsp;Sebastiaan Remmers ,&nbsp;André Deschamps ,&nbsp;John Dowling ,&nbsp;Ernst-Günter Carl ,&nbsp;Nuno Pereira-Azevedo ,&nbsp;Monique J. Roobol","doi":"10.1016/j.euros.2024.11.006","DOIUrl":"10.1016/j.euros.2024.11.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>In 2019 and 2021, Europa Uomo initiated the Europa Uomo Patient Reported Outcome Study (EUPROMS) and the EUPROMS 2.0 survey, with the goal of collecting data on patients’ self-reported perspective on physical and mental well-being outside of a clinical trial setting, to be able to investigate the burden of prostate cancer (PCa) treatment from a patient-to-patient perspective. Acknowledging the importance of collecting quality of life (QoL) follow-up data, a 1-yr follow-up (1yrFU) study was conducted to assess the effect of additional PCa treatment on QoL.</div></div><div><h3>Methods</h3><div>Men with PCa who participated in the EUPROMS 2.0 survey and indicated that they were open to collection of a follow-up measurement were reinvited to complete the 1yrFU survey. The EUPROMS 2.0 1yrFU survey included the validated European Quality of Life 5 Dimension 5 Level (EQ-5D-5L), European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Expanded Prostate Cancer Index Composite Short Form (EPIC-26), and International Index of Erectile Function (IIEF)-15 overall satisfaction domains. Descriptive statistics were used to assess demographic characteristics and to analyze the patient-reported outcome data.</div></div><div><h3>Key findings and limitations</h3><div>A total of 1006 (54%) men completed the survey. The median age at the time of questionnaire completion was 72 yr (interquartile range 66–76 yr). Of them, 641 men (64%) underwent no new treatment, while 365 men (36%) underwent new treatment, including 247 (247/365, 68%) for PCa. In total, 114 patients (46%) underwent new androgen deprivation therapy (ADT) and 81 (33%) new external beam radiotherapy (EBRT). It is indicated that the impact of new ADT and EBRT on sexual function is immediate and detrimental, and continues to last over time. However, for men who underwent EBRT or radical prostatectomy earlier and did not undergo new treatment, slight improvements on various domains are reported.</div></div><div><h3>Conclusions and clinical implications</h3><div>The EUPROMS 2.0 1yrFU study provides additional information on treatments that are already in common use and will help future PCa patients to make informed and shared decisions on PCa treatment.</div></div><div><h3>Patient summary</h3><div>The follow-up data on quality of life collected by Europa Uomo can be used to inform future prostate cancer (PCa) patients about the impact of undergoing (multiple) PCa treatment(s).</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 114-124"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of Patient-reported Outcomes for Men with Prostate Cancer: Results from the PIONEER Consortium","authors":"Sebastiaan Remmers ,&nbsp;Katharina Beyer ,&nbsp;Tariq A. Lalmahomed ,&nbsp;Peter Prinsen ,&nbsp;Nicole J.E. Horevoorts ,&nbsp;Nora Tabea Sibert ,&nbsp;Christoph Kowalski ,&nbsp;Francesco Barletta ,&nbsp;Oliver Brunckhorst ,&nbsp;Giorgio Gandaglia ,&nbsp;Jochem R.N. van der Voort van Zyp ,&nbsp;Emma J. Smith ,&nbsp;Andre Deschamps ,&nbsp;Laurence Collette ,&nbsp;Philip Cornford ,&nbsp;Susan Evans-Axelsson ,&nbsp;James N’Dow ,&nbsp;Mieke Van Hemelrijck ,&nbsp;Monique J. Roobol ,&nbsp;Lionne D.F. Venderbos","doi":"10.1016/j.euros.2024.11.009","DOIUrl":"10.1016/j.euros.2024.11.009","url":null,"abstract":"<div><h3>Background and objective</h3><div>Patient-reported outcome measures (PROMs) are increasingly being used to capture the patients’ perspective of their functional status and quality of life (QoL). Big data can help us better understand patient-reported outcomes (PROs). Using prospectively collected data from the Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe (PIONEER) consortium, we aimed to describe the functional status and QoL in men with prostate cancer (PCa) treated with active surveillance (AS), radical prostatectomy (RP), and radiotherapy (RT), and to demonstrate the applicability of PROM data on a large scale and at a European level.</div></div><div><h3>Methods</h3><div>We identified data sources that collected QoL data using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-PR25, or Expanded Prostate Cancer Index Composite (EPIC)-26/50 questionnaires. Aggregated summary scores for urinary, bowel, and sexual dysfunction, global health status, and QoL were shared for each data source.</div></div><div><h3>Key findings and limitations</h3><div>We identified eight data sources originating from various settings: routine hospital data, embedded research PRO collection, survey data collected by a patient organization, multi-institutional prospective cohort study, and registry data. PRO data were available for 709 men on AS, 20 508 on RP, and 3417 on RT, with a median time between diagnosis and PROM assessment ranging from 1 to 8.7 yr. Most men were diagnosed with Gleason ≤7 disease, and T1 or T2 PCa. We observed that sexual dysfunction was the most affected PRO and found large differences between data sources.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our results support the feasibility of PRO assessment using big data in Europe. Implementation of PROMs in clinical practice and the use of standardized methods could improve value-based health care provision.</div></div><div><h3>Patient summary</h3><div>In this study, we combined several data sources that reported urinary, bowel, and sexual dysfunction, global health status, and quality of life. We identified eight data sources and show that sexual function is the most affected domain after treatment.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 106-113"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copyright page","authors":"","doi":"10.1016/S2666-1683(25)00005-9","DOIUrl":"10.1016/S2666-1683(25)00005-9","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page I"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"19 Optimizing oncologic outcomes in high-grade non-muscle invasive bladder cancer: Theimpact of a surgeon-led treatment pathway","authors":"Scilipoti P.,&nbsp;Rosiello G.,&nbsp;Viti A.,&nbsp;Santangelo A.,&nbsp;Briganti A.,&nbsp;Moschini M.,&nbsp;Montorsi F.","doi":"10.1016/S2666-1683(25)00022-9","DOIUrl":"10.1016/S2666-1683(25)00022-9","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S22"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"8 Novel enhancement of multimodality treatment of prostate cancer, combining radiotherapy,vascular-targeted photodynamic therapy, and immunotherapy","authors":"Sjoberg H.T.,&nbsp;Macklin S.,&nbsp;Philippou Y.,&nbsp;Murphy E.A.,&nbsp;Tullis I.D.C.,&nbsp;Jones K.I.,&nbsp;Stribbling S.M.,&nbsp;Parkes E.E.,&nbsp;Edmondson E.F.,&nbsp;Scheiblin D.A.,&nbsp;Lockett S.J.,&nbsp;Wink D.A.,&nbsp;Rittscher J.,&nbsp;Preise D.,&nbsp;Agemy L.,&nbsp;Yechezkel T.,&nbsp;Giaccia A.,&nbsp;Mills I.G.,&nbsp;Muschel R.J.,&nbsp;Vojnovic B.,Scherz A.,&nbsp;Bryant R.J.","doi":"10.1016/S2666-1683(25)00039-4","DOIUrl":"10.1016/S2666-1683(25)00039-4","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S8"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2 Studies with high-level evidence can unmask false therapeutic myths: Using the example ofurolithiasis prophylaxis","authors":"Roth B.,&nbsp;Stritt K.,&nbsp;Fuster D.","doi":"10.1016/S2666-1683(25)00023-0","DOIUrl":"10.1016/S2666-1683(25)00023-0","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S1"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"24 Developing new approaches to stress urinary incontinence treatment in women during early phase research into artificial muscle technology","authors":"Drake M.,&nbsp;Rossiter J.,&nbsp;McCarthy A.,&nbsp;Garrad M.,&nbsp;Faul C.","doi":"10.1016/S2666-1683(25)00028-X","DOIUrl":"10.1016/S2666-1683(25)00028-X","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S27"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Urinary Function Outcomes Following Low-dose-rate Brachytherapy for Prostate Cancer","authors":"Gianni Rüedi ,&nbsp;Manolis Pratsinis ,&nbsp;Hans-Peter Schmid ,&nbsp;Sabine Güsewell ,&nbsp;Paul M. Putora ,&nbsp;Ludwig Plasswilm ,&nbsp;Christoph Schwab ,&nbsp;Orlando Burkhardt ,&nbsp;Armin Thoeni ,&nbsp;Werner Hochreiter ,&nbsp;Ladislav Prikler ,&nbsp;Stefan Suter ,&nbsp;Patrick Stucki ,&nbsp;Michael Müntener ,&nbsp;Nadja Blick ,&nbsp;Hans Schiefer ,&nbsp;Gautier Müllhaupt ,&nbsp;Daniel S. Engeler","doi":"10.1016/j.euros.2024.11.004","DOIUrl":"10.1016/j.euros.2024.11.004","url":null,"abstract":"<div><h3>Background and objective</h3><div>Our aim was to develop a tool using readily available clinical parameters to predict the probability of poor urinary function following low-dose-rate brachytherapy (LDR-BT) for localized prostate cancer.</div></div><div><h3>Methods</h3><div>Data from the multicentre, prospective Swiss LDR-BT cohort were analyzed for men treated with LDR-BT. Inclusion criteria were minimum follow-up of 3 yr or postoperative treatment with transurethral resection of the prostate (TURP). A total of 914 men were analyzed, with complete data available for 607 men. Pre-interventional variables assessed were International Prostate Symptom Score (IPSS), prostate volume (PV), maximum urinary flow rate, prostate-specific antigen, postvoid residual urine volume, and age. The primary outcome was poor urinary function after LDR-BT, defined as an IPSS-Quality of Life score &gt;3 (“mostly dissatisfied” or worse) at 3 yr or the occurrence of TURP during follow-up. Associations were evaluated using univariable and multivariable logistic regression. Receiver operating characteristic curve analysis was also performed.</div></div><div><h3>Key findings and limitations</h3><div>Poor urinary function outcomes were observed in 46 patients (5.0%). Significant predictors included pre-interventional IPSS (adjusted odds ratio [aOR] per point 1.18; <em>p</em> &lt; 0.001) and PV (aOR per ml, 1.04; <em>p</em> = 0.004). Limitations of the study include potential selection bias and the absence of external validation.</div></div><div><h3>Conclusions and clinical implications</h3><div>Pre-interventional IPSS and PV were significant predictors of poor urinary function after LDR-BT for prostate cancer. A risk calculator based on these parameters was developed to assist individualized treatment planning. Further studies are needed to validate these findings before they can be applied in routine clinical practice.</div></div><div><h3>Patient summary</h3><div>We created a tool to predict the likelihood of urinary problems after a type of radiotherapy called brachytherapy for prostate cancer. The size of the prostate and urinary symptoms before treatment were associated with poor urinary function after treatment. This tool could help doctors and patients in making informed decisions about treatment for prostate cancer.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 31-37"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6 Survival results of PSMA/PET-based salvage radiotherapy for recurrent prostate cancer","authors":"Grivas N.,&nbsp;van Leeuwen P.,&nbsp;Wit E.,&nbsp;Vis A.,&nbsp;Nieuwenhuijzen J.,&nbsp;Pos F.,&nbsp;van der Poel H.","doi":"10.1016/S2666-1683(25)00037-0","DOIUrl":"10.1016/S2666-1683(25)00037-0","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Page S5"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143092299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}